RxDoctor Payments Data

John Kulze, MD

Ophthalmology · Charleston, SCNPI 1497733794

Payments from drug & device makers

$1,857in general payments, 2019–2025

Across 70 payments — averaging $26.53 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$555
  • AbbVie$227
  • Bausch & Lomb, A Division Of Bausch Health US, LLC$214
  • Johnson & Johnson Surgical Vision, Inc.$181
  • Bausch & Lomb Americas Inc.$147
  • NEW World Medical,inc.$140
  • plus $392 from 9 others

What the payments were for

  • Food & beverage$1,857100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$1,857 in reported general payments places this provider in the 45th percentile of 293 ophthalmology providers in South Carolina.

See all ophthalmology providers in South Carolina

Medicare billing

Part B allowed, 2024
$430,881
Medicare patients
1,629
Services billed
3,756

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
LumiganBimatoprost118$61,713
RestasisCyclosporine42$37,139
Cyclosporine30$20,217
XiidraLifitegrast15$20,093
Travoprost41$6,388
Latanoprost475$5,955
Dorzolamide-TimololDorzolamide/Timolol/Pf22$5,641
TafluprostTafluprost/Pf32$5,555
Brimonidine Tartrate104$5,182
RhopressaNetarsudil Mesylate13$4,147
CombiganBrimonidine Tartrate/Timolol11$3,374
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat162$3,316
Bromfenac Sodium19$2,957
Brimonidine Tartrate-TimololBrimonidine Tartrate/Timolol15$2,488
Dorzolamide Hcl87$1,797

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieLumigan, Restasis, Combigan$227$102,227171 claims
Bausch & Lomb Americas Inc.Xiidra$147$20,09315 claims
Aerie Pharmaceuticals, Inc.Rhopressa$32$4,14713 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 293 ophthalmology providers in South Carolina.

Other ophthalmology in Charleston

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →